B2BROKER
26.10.2021 09:02:17 CEST | Business Wire | Press release
B2Broker, a leading technology and liquidity provider in the Forex and Crypto industry, has announced the introduction of a series of outstanding new conditions for its Margin and Crypto Spot liquidity offerings. With today’s announcement comes a new pricing structure that delivers an ultra competitive proposition which is unmatchable in the industry.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211026005100/en/
B2Broker launched its initial Crypto CFD offering back in 2017, starting with 30 Crypto CFD pairs. The company was the first in this space to implement a Prime Broker business model approach in the Crypto CFD offering. Today, it offers a total of 115 Crypto pairs making it the industry’s leading Crypto CFD provider as well as a tier 1 liquidity provider in the Spot FX, Metals, Equity Indices, Commodities, Single Stocks, and ETFs space all from a single margin account.
To date, B2Broker is used by more than 50% of FX Retail Brokers/Props Houses/Funds, etc, who offer Crypto CFDs and require a main liquidity provider or secondary source of liquidity.
Margin Liquidity
As the popularity of margin trading continues to reach new heights, the new trading conditions from B2Broker will enable its clients to benefit from a whole range of new features and advantages. These include:
New Crypto CFDs
We have added a further 15 new crypto CFDs to our liquidity pool that have proved highly popular recently:
XRP, Cardano, Dogecoin, Solana, Polkadot, Chainlink, Polygon, Uniswap, HIBA INU, Algorand, Avalanche, Terra, Filecoin, Vechain and Maker.
Note: all trade against the USD.
New Margin Requirements
New margin requirements on major crypto CFDs have been decreased from 20% to 10% . This will allow greater opportunities for traders around the world to leverage our unbeatable conditions.
The list of symbols that we have applied changes to include:
BTC/USD, BCH/USD, ETH/USD, LTC/USD, XRP/USD
BTC/EUR, BCH/EUR, ETH/EUR, LTC/EUR, XRP/EUR
BTC/GBP, BCH/GBP, ETH/GBP, LTC/GBP
New Pricing Policy
New commercial offers have been introduced to serve all types of business models. Whether you need a white label solution, a FIX API/gateway connection or an enterprise solution, B2Broker offers a bespoke proposition that serves your business according to your requirements.
Our new Enterprise offering includes PrimeXM or OneZero HUB along with a liquidity solution that gives brokers greater flexibility in terms of managing their liquidity price streams and risk management solutions. The main idea behind this package is to offer broker dealers a solution where they will be able to use our liquidity along with leading HUBs/XCOREs in a more efficient and cost-effective way. For example, if you go directly to PrimeXM or OneZero and buy a Hub with them and then approach B2Broker to buy liquidity, it will prove to be more expensive than simply buying a single Enterprise pack from B2Broker.
The Enterprise liquidity solution is ideal for Brokers who have their own Trading Server such as MT5, MT4, C-Trader etc, and want to be able to manage their price streams, markups, swaps, risk management and more.
New Liquidity Pool Locations
Our liquidity pools are now based in main locations around the world such as LD4, NY4, TY3, SG1 and Mainland China (Beijing). You can choose the best suitable location for your API/Gateway connection.
For our WL clients based in LD4, we have created a global network of access servers which provide the lowest latency connection from any point in the world.
Liquidity Distribution
We offer liquidity distribution across the following platforms to cater for the broad-based demands of our clients PrimeXM, OneZero, FixAPI, MT5, MT4 for FX/CFD, Crypto CFDs etc and B2Trader, Rest API and WEBSocket for Crypto Spot liquidity.
Crypto Spot Liquidity
On the Crypto Spot liquidity side of things, we have introduced a range of outstanding new developments which are applicable to B2BX:
A. Revised ultra-competitive commission ladder which goes down to 0.04%.
B. In total we have enhanced the depth of order book to 100 levels per each side (Buy and Sell) to satisfy the requirements of major players. The compressed order book contains over 120 BTC with an average spread of just $7 USD and market impact of around $140 USD.
C. Increased our trading pairs to consist of additional stable coins and all the top tokens.
B2Broker CEO, Arthur Azizov commented, “We constantly seek to improve our offers and are positioned to offer an unbeatable pricing structure for our services, as well as other favourable conditions which will ultimately benefit our clients. Our liquidity services can be accessed quickly and easily with the most advantageous prices available within the industry and the highest level of technical support”.
B2Broker’s liquidity solutions are used by various types of financial institutions who benefit from our expertise and technology, and our ability to deliver customised liquidity solutions tailored to our clients exact needs. B2Broker offers liquidity on Spot FX, Metals, Commodities, Single Stocks with over 400 instruments, working as a PoP, rather than a market maker. We are therefore on the broker’s side at all times, enabling the best possible liquidity provision in keeping with our clients’ interests.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211026005100/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Europe’s Largest Celebration of Irish Culture Arrives in Belfast2.8.2026 10:01:00 CEST | Press release
Fleadh Cheoil na hÉireann arrives in Belfast today (2 August), bringing eight days of traditional music, culture and celebration to the city, with organisers expecting up to 800,000 visitors over the course of the festival. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260729147569/en/ Belfast Fleadh - Maddens Bar accordian, guitar and fiddle player (Chris Heaney) One of Europe’s largest cultural events, Fleadh Cheoil na hÉireann is taking place in Belfast for the first time, transforming the city into a vibrant stage for Irish music, dance, language and culture. More than 200 events and 180 traditional music competitions are taking place across venues, streets and neighbourhoods throughout the week-long celebration. The landmark festival showcases the very best of Irish culture, with a packed programme of All-Ireland competitions, concerts, community events and performances from both established and emerging artists. As Ir
2PointZero Group Signals Global Scale With Revenue Surge to AED 21.9 Billion and Net Profit of AED 7.7 Billion in H1 202631.7.2026 13:42:00 CEST | Press release
Group revenue growth supported by stable gross profit margin of 29%, and adjusted EBITDA of AED 5.0 billionGlobal expansion milestones include the completed sale of TAQA stake, and the acquisition of Traverse Midstream Partners in North America, Baobab Group in Africa, and 60.8% of ISEM in ItalyTIME ranks the Group 36th on the World’s Growth Leaders list for 2026, highlighting market stability, operational scale and disciplined approach to capital 2PointZero Group (ADX: 2POINTZERO), a leading Abu Dhabi-based investment holding firm, announced its financial results for the first half of 2026, reporting revenue of AED 21.9 billion and delivering a Group Net Profit of AED 7.7 billion. This robust performance is reflected in the Group’s adjusted EBITDA, which reached AED 5.0 billion after excluding fair value changes and one-offs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260731538982/en/ Samia Bouazza, CEO of 2PointZero (P
Datroway® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 08:30:00 CEST | Press release
Approval based on TROPION-Breast02 phase 3 trial results where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival Datroway now approved for two breast cancer indications in the EU Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on result
Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 08:30:00 CEST | Press release
Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said
SES: Disclosure of Share Buyback Transactions31.7.2026 07:30:00 CEST | Press release
In the time period from June 2, 2026 until and including June 23, 2026, a number of 213,167 shares were bought back within the framework of the share buyback of SES to meet obligations under SES’s Equity Based Compensation Plan (EBCP). Shares were bought back as follows: Day of purchase Aggregated volume in shares Daily weighted average acquisition price of shares (EUR) Market June 2, 2026 27,097 8.8727 DXE June 2, 2026 72,903 8.8556 ENX June 5, 2026 16,624 8.3723 DXE June 5, 2026 31,510 8.4266 ENX June 15, 2026 26,451 7.8423 XPAR June 17, 2026 26,812 7.3910 XPAR June 23, 2026 11,770 7.2200 XPAR The transactions in a detailed form are published on SES’s website: https://www.ses.com/investors/shareholder-information/share-buy-backs. Follow us on: Twitter | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, busin
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom